Clinical Podcasts

UpToDate faculty discuss important “What’s New” and “Practice Changing UpDates”, based on recent medical journal articles, in our clinical podcasts. Our contributors are recognized physician leaders in their fields and offer their expertise regarding each update and its impact on clinical practice. Each clinical podcast includes the most current clinical information available as of the release date listed.

Support for UpToDate Talk is provided by UpToDate, Wolters Kluwer. UpToDate is entirely funded by the subscriptions of its users and does not accept advertising or funding unrelated to subscriptions. The opinions in such podcasts are entirely those of the discussants, and these discussants are authors and editors for UpToDate. View the UpToDate conflict of interest policy.

To be alerted as each new episode airs, simply subscribe to our podcast channel on iTunes. Also, check out our Healthcare Industry Podcasts that explore healthcare initiatives with an impact on quality and patient safety. We hope you will find these series an enjoyable way to keep UpToDate!

Buprenorphine for neonatal abstinence syndrome; Sublingual immunotherapy for house dust mite allergy

Date Released: Jul 26 2017

In this episode, Dr. Lauren Jansson discusses buprenorphine for neonatal abstinence syndrome, and Dr. Peter Creticos discusses a sublingual immunotherapy tablet for house dust mite allergies. Dr. Sadhna Vora hosts.

Dr. JanssonDr. Lauren Jansson is an Associate Professor of Pediatrics at the Johns Hopkins University School of Medicine and Director of Pediatrics at the Center for Addiction and Pregnancy.
Dr. CreticosDr. Peter Creticos is an Associate Professor of Medicine at the Johns Hopkins University School of Medicine.

Segment on buprenorphine for neonatal abstinence syndrome (Dr. Jansson):

  1. Kraft WK, Adeniyi-Jones SC, Chervoneva I, et al. Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome. N Engl J Med 2017; 376:2341.

Segment on sublingual immunotherapy tablet for house dust mite allergy (Dr. Creticos):

  1. Nolte H, Bernstein DI, Nelson HS, et al. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. J Allergy Clin Immunol 2016; 138:1631.

Lauren M Jansson MD Nothing to disclose

Peter S Creticos, MD Grant/Research/Clinical Trial Support: Stallergenes-Greer [Immunotherapy (SLIT)]; Circassia [Immunotherapy (Peptides)]. Consultant/Advisory Boards: Circassia; Greer; ITI [Immunotherapy (SCIT; SLIT)]; Allakos [Cytokine antagonists]; ASIT [AIT].

Goal blood pressure in older adults; Dexamethasone and acute pharyngitis pain in adults

Date Released: Jul 12 2017

This episode features Dr. Brent Egan discussing the target blood pressure in older adults, and Dr. Mark Aronson discussing the use of dexamethasone for acute pharyngitis pain in adults. Dr. Nancy Sokol hosts.

Dr. NathanDr. Brent Egan is a Professor of Medicine at the University of South Carolina School of Medicine, and Chief Science Officer at the Care Coordination Institute.
Dr. AronsonDr. Mark Aronson is a Professor of Medicine at Harvard Medical School, Associate Chief of the Division of General Medicine and Primary Care and Vice Chair for Quality at the Beth Israel Deaconess Medical Center in Boston.

Segment on Goal blood pressure in older adults (Dr. Brent Egan):

  1. Bavishi C, Bangalore S, Messerli FH. Outcomes of Intensive Blood Pressure Lowering in Older Hypertensive Patients. J Am Coll Cardiol 2017; 69:486.

Segment on Dexamethasone for acute pharyngitis pain in adults (Dr. Mark Aronson):

  1. Hayward GN, Hay AD, Moore MV, et al. Effect of Oral Dexamethasone Without Immediate Antibiotics vs Placebo on Acute Sore Throat in Adults: A Randomized Clinical Trial. JAMA 2017; 317:1535.

Brent M Egan, MD Grant/Research/Clinical Trial Support: Boehringer [Diabetes (Empagliflozin)]. Speaker's Bureau: Medtronic [Hypertension (Renal artery denervation to lower blood pressure)]; Merck International [Hypertension, heart failure (Bisoprolol)]. Consultant/Advisory Boards: Valencia [Hypertension (Device-based treatment to lower blood pressure)]; Inside Edge Consulting [Clinical trials (Patient recruitment and retention)].

Mark D Aronson, MD Nothing to disclose

Complications of t1 and t2 diabetes diagnosed in childhood; Gene therapy for sickle cell disease

Date Released: Jun 28 2017

Dr. Joseph Wolfsdorf discusses complications related to type 1 and type 2 diabetes in pediatric patients, and Dr. Michael DeBaun discusses a report of gene therapy for sickle cell disease. Dr. Nancy Sokol hosts.

Dr. WolfsdorfDr. Joseph Wolfsdorf is a Professor of Pediatrics at Harvard Medical School, and Director of the Diabetes Program at the Boston Children's Hospital.
Dr. DeBaunDr. Michael DeBaun is a Professor of Pediatrics and Medicine at Vanderbilt University and is Director of the Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease.

Segment on diabetes in children (Dr. Wolfsdorf):

  1. Dabelea D, Stafford JM, Mayer-Davis EJ, et al. Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood. JAMA 2017; 317:825.

Segment on gene therapy for sickle cell disease (Dr. DeBaun):

  1. Ribeil JA, Hacein-Bey-Abina S, Payen E, et al. Gene Therapy in a Patient with Sickle Cell Disease. N Engl J Med 2017; 376:848.

Joseph I Wolfsdorf, MB, BCh Nothing to disclose

Michael R DeBaun, MD, MPH Nothing to disclose

Long-term follow-up of imatinib for CML; Ocrelizumab for primary progressive multiple sclerosis

Date Released: Jun 14 2017

This episode features Dr. Richard Larson discussing the long-term outcomes of imatinib treatment for chronic myeloid leukemia, and Dr. Francisco Gonzalez-Scarano discussing the use of ocrelizumab for treatment of primary progressive multiple sclerosis. Dr. Jennifer Mitty hosts.

Dr. González-ScaranoDr. Francisco González-Scarano is Professor of Neurology and the John P. Howe Distinguished Chair in Health Policy at the University of Texas Health Science Center at San Antonio and Professor Emeritus of Neurology at the University of Pennsylvania.
Dr. LarsonDr. Richard Larson is Professor of Medicine and the Director of the Hematological Malignancies Clinical Research Program at the University of Chicago Pritzker School of Medicine.

Segment on Long-term follow-up of Imatinib in chronic myeloid leukemia (Dr. Richard Larson) :

  1. Hochhaus A, Larson RA, Guilhot F, et al. Long-term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med 2017; 376:917.

Segment on Ocrelizumab for primary progressive multiple sclerosis (Dr. Francisco González-Scarano):

  1. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 2017; 376:209.

Francisco González-Scarano, MD Equity Ownership/Stock Options: Multiple, but traded by advisors without personal input [Pharmaceutical]. Other Financial Interests: NeuroLink [Venture Capital].

Richard A Larson, MD Grant/Research/Clinical Trial Support: Amgen [leukemia (blinatumomab)]; Astellas [leukemia (gilteritinib)]; Erytech [leukemia (eryaspase)]; Ariad [leukemia (ponatinib)]; Novartis [leukemia (nilotinib)]; Ambit Bioscience [leukemia (quizartinib)]; Daiichi Sankyo [leukemia (quizartinib)]; Celgene [leukemia (AG-221)]. Consultant/Advisory Boards: Novartis [leukemia (imatinib, nilotinib)]; Ariad Data Safety Monitoring Board [leukemia (ponatinib)]; CVS/Caremark [leukemia (drug prior authorization program)]; Pfizer [leukemia (gemtuzumab ozogamicin, inotuzumab)]; Celgene Data Safety Monitoring Board [leukemia (azacitidine, durvalumab)]; Bristol Meyers Squibb Data Safety Monitoring Board [leukemia (dasatinib)]; Amgen [leukemia (blinatumomab)]; Astellas [leukemia (gilteritinib)]; Jazz [leukemia (CPX-351)].